Bayer Receives EU Approval for Stivarga ® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)

Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States fo r patients with HCC
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news